CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)
Completed
- Conditions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 972
- Registration Number
- NCT01102543
- Locations
- 🇫🇷
Laboratoire Chiesi S.A., Courbevoie, France
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 113
- Registration Number
- NCT01070524
- Locations
- 🇬🇧
The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road, Manchester, United Kingdom
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 457
- Registration Number
- NCT00972140
- Locations
- 🇵🇱
Prof. Iwona Graelewska Rzymowska, Lodz, Lódz, Poland
Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT00938353
- Locations
- 🇮🇹
Ospedale San Giuseppe Moscati, Avellino, Italy
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1199
- Registration Number
- NCT00929851
- Locations
- 🇬🇧
UCL Medical School, London, United Kingdom
FACTO Study (Foster® As Complete Treatment Option)
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 431
- Registration Number
- NCT00901368
- Locations
- 🇫🇷
Hôpital Nord, Marseille, France
🇳🇱Atrium Medisch Centrum Heerlen,, Heerlen, Netherlands
🇩🇪Allergologie imUmkreis der Praxis Pneumologie, Gelsenkirchen, Nordrhein-Westfalen, Germany
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 324
- Registration Number
- NCT00885365
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Clinique des maladies respiratoires, Montpellier, France
🇨🇿Centrum pro cystickou fibrosu, Pediatricka klinika UK 2.LF, Fakultní nemocnice v Motole, Praha, Czechia
🇫🇷CHR Clemenceau, Caen, France
Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 69
- Registration Number
- NCT00868023
- Locations
- 🇬🇧
Pr DS SINGH, Manchester, United Kingdom
Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 286
- Registration Number
- NCT00862264
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 783
- Registration Number
- NCT00862394
- Locations
- 🇩🇪
Oliver Kornmann - National Coordinator in Germany, Mainz, Germany
© Copyright 2024. All Rights Reserved by MedPath